<DOC>
	<DOCNO>NCT00320008</DOCNO>
	<brief_summary>The purpose study determine whether intensified multifactorial intervention comprise behaviour modification polypharmacy reduce risk late diabetic complication compare standard treatment patient type 2 diabetes microalbuminuria .</brief_summary>
	<brief_title>Intensified Multifactorial Intervention Patients With Type 2 Diabetes Microalbuminuria</brief_title>
	<detailed_description>The overall description Steno-2 Study state four protocol approve regulatory authority Denmark . The protocol identification number KA 92071gm ( 4 year intervention ) , KA-99035g ( 8 year intervention ) , KA-99035-GS ( 13 year follow-up since intervention start ) H-KA-99035-GS ( 21 year follow-up since intervention start ) . The aim study determine whether intensified multifactorial intervention comprise behaviour modification polypharmacy reduce risk late diabetic complication compare standard treatment patient type 2 diabetes microalbuminuria . The primary end point four year intervention progression diabetic nephropathy microvascular complication secondary end point . The primary end point eight year intervention composite CVD endpoint microvascular complication secondary end point . The interventional part study end December 2001 total eight year intervention . From time , patient follow post-trial study . Also , post-trial period patient original treatment arm receive similar treatment resemble treatment give original intensive arm study . The aim post-trial follow-up investigate effect intensify multifactorial intervention ) mortality ii ) year life gain , respectively , interventional approach . Endpoints two part post-trial follow-up : Part one 13 year since start intervention : Primary endpoint : Total mortality . Secondary endpoint : Cardiovascular endpoint define previously ; Microvascular disease . Part two 21 year since start intervention : Primary endpoint : Difference median time 50 % mortality two original treatment group Secondary endpoint : Cardiovascular endpoint define previously ; Recurrent cardiovascular event ; Microvascular disease .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes Microalbuminuria Stimulated serum Cpeptide concentration le 600 pmol/L Pancreatic insufficiency diabetes secondary pancreatitis Alcohol abuse Nondiabetic kidney disease Lifethreatening disease death probable within 4 year study start</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>